drugset
Drugs / Normoxic Allogenic UCMSC
last change Nov 2021 re-read 3 minutes ago

Normoxic Allogenic UCMSC

also known as Allogenic umbilical cord-derived mesenchymal stem cell (UCMSC)

Cell therapy

Developed for
COVID-19
Investigated by
Dr. Hasan Sadikin General Hospital, Bandung, Indonesia · Dr. Moewardi General Hospital, Surakarta, Indonesia · Dr. Sardjito General Hospital, Yogyakarta, Indonesia · National Research and Innovation Agency · PT Bifarma Adiluhung

Trials 1

today NCT05132972 · Ph 2/3
202120222023202420252026
PhaseRegistry idDatesIndicationSponsorStatusOutcome
Phase 2/3 NCT05132972 Jan → Nov 2021 COVID-19 National Research and Innovation Agency Unknown No outcome recorded

Evidence & citations 4 cited values

Every value below carries the sentence it was read from. 1 source stands behind the page.

FieldValueCited text
Known as Normoxic Allogenic UCMSC ClinicalTrials.gov intervention name — accepted as the source's own label NCT05132972 ↗
Known as Allogenic umbilical cord-derived mesenchymal stem cell (UCMSC) “Allogenic umbilical cord-derived mesenchymal stem cell (UCMSC) from normoxic, culture condition” NCT05132972 ↗
Modality Cell therapy “mesenchymal stem cell (UCMSC)” NCT05132972 ↗
Route Intravenous “administered through intravenousinfusion” NCT05132972 ↗